Skip Ribbon Commands
Skip to main content
Menu
Dr Charlene Tang Yu Lin

Dr Tang Yu Lin Charlene

​MBBS, MRCP (UK), MMED (Int Med)

Consultant

Specialty: Nuclear Medicine and Molecular Imaging

Conditions Treated by this Doctor:
Bone Mineral Densitometry (BMD) , General Nuclear Medicine , Liver Tumours , Neuroendocrine Tumors , Nuclear Cardiology , Nuclear Oncology , PET/CT , Prostate Cancer , Radionuclide Bone Pain Palliation , Radiosynovectomy , Radiosynovectomy (Radiation synovectomy / Radiosynoviorthesis) , Thyroid Cancer , Thyrotoxicosis , Y90 Microspheres .

Clinical Appointments

  • Associate Consultant Nuclear Medicine and Molecular Imaging Singapore General HospitalSingapore General Hospital

Academic Appointments

  • Physician Faculty Member, SingHealth Diagnostic Radiology Residency Programme

Profile

​​Dr Charlene Tang obtained her medical degree from the Yong Loo Lin School of Medicine, National University of Singapore in 2014. She completed her Internal Medicine junior residency training with the National Healthcare Group and obtained specialist qualifications in Internal Medicine from the Royal College of Physicians and the National University of Singapore in 2017. Following that, she completed further training in Nuclear Medicine in 2020.

Education

  • ​Master of Medicine (Internal Medicine), National University of Singapore, 2016
  • Membership of Royal College of Physicians (UK), 2016
  • MBBS, National University of Singapore, Singapore, 2014

Professional Appointments and Committee Memberships

Awards

  • ​SingHealth RiSE Awards 2020 – Outstanding Resident

Research Interests

Publications

  • Tang CYL, Chua WM, Cheng LTJ, Fong W, Zaheer S, Lam WW. 18F-FDG PET/CT Manifestations of IgG4-related Disease. Br J Radiol. 2021 May 28.
  • Tang CYL, Thang SP, Zaheer S, Kwan CK, Ng DC. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population. Endocrine. 2020 Feb 28.
  • Tay WL, Tong AKT, Hui KYD, Tang YLC, Chng CL. Radioiodine associated de novo Graves' opthalmopathy in an Asian cohort. Hell J Nucl Med. 2017 Sep-Dec;20(3):227-231

Research Trials